Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04) (FOCUS / KOV-04)
Phase III Randomized Trial of HIPEC in Primary Stage Three & Four Primary Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS, KOV-04)
Sponsor: National Cancer Center, Korea
Listed as NCT05827523, this PHASE3 trial focuses on Ovarian Cancer and remains actively recruiting participants. Sponsored by National Cancer Center, Korea, it has been updated 8 times since 2023, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE3
-
Sep 2025 — Feb 2026 [monthly]
Recruiting PHASE3
-
Feb 2025 — Sep 2025 [monthly]
Recruiting PHASE3
-
Sep 2024 — Feb 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
▶ Show 3 earlier versions
-
Jul 2023 — Jul 2024 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jun 2023 — Jul 2023 [monthly]
Not Yet Recruiting PHASE3
-
May 2023 — Jun 2023 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Center, Korea
For direct contact, visit the study record on ClinicalTrials.gov .